505 related articles for article (PubMed ID: 31222577)
21. Identification and validation of methylated PENK gene for early detection of bladder cancer using urine DNA.
Oh TJ; Lim E; Bang BR; Lee JJ; Na YG; Shin JH; Lim JS; Song KH; An S
BMC Cancer; 2022 Nov; 22(1):1195. PubMed ID: 36403035
[TBL] [Abstract][Full Text] [Related]
22. Importin-11 overexpression promotes the migration, invasion, and progression of bladder cancer associated with the deregulation of CDKN1A and THBS1.
Zhao J; Shi L; Zeng S; Ma C; Xu W; Zhang Z; Liu Q; Zhang P; Sun Y; Xu C
Urol Oncol; 2018 Jun; 36(6):311.e1-311.e13. PubMed ID: 29602637
[TBL] [Abstract][Full Text] [Related]
23. Histopathological distinction of non-invasive and invasive bladder cancers using machine learning approaches.
Yin PN; Kc K; Wei S; Yu Q; Li R; Haake AR; Miyamoto H; Cui F
BMC Med Inform Decis Mak; 2020 Jul; 20(1):162. PubMed ID: 32680493
[TBL] [Abstract][Full Text] [Related]
24. Urinary APE1/Ref-1: A Potential Bladder Cancer Biomarker.
Choi S; Shin JH; Lee YR; Joo HK; Song KH; Na YG; Chang SJ; Lim JS; Jeon BH
Dis Markers; 2016; 2016():7276502. PubMed ID: 27057081
[TBL] [Abstract][Full Text] [Related]
25. Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer.
Liu C; Shi B; Hao C; Wang Q; Lv Q; Xing N; Shou J; Qu L; Gao Y; Qin C; Zhao J; Shou C
Oncotarget; 2016 Jul; 7(28):43432-43441. PubMed ID: 27223068
[TBL] [Abstract][Full Text] [Related]
26. Decreased TRPM7 inhibits activities and induces apoptosis of bladder cancer cells via ERK1/2 pathway.
Cao R; Meng Z; Liu T; Wang G; Qian G; Cao T; Guan X; Dan H; Xiao Y; Wang X
Oncotarget; 2016 Nov; 7(45):72941-72960. PubMed ID: 27662662
[TBL] [Abstract][Full Text] [Related]
27. Machine learning models in breast cancer survival prediction.
Montazeri M; Montazeri M; Montazeri M; Beigzadeh A
Technol Health Care; 2016; 24(1):31-42. PubMed ID: 26409558
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of miR-182/miR-100 Ratio for Diagnosis and Survival Prediction in Bladder Cancer.
Chen Z; Wu L; Lin Q; Shi J; Lin X; Shi L
Arch Iran Med; 2016 Sep; 19(9):645-51. PubMed ID: 27631180
[TBL] [Abstract][Full Text] [Related]
29. MicroRNAs as Biomarkers for the Diagnostics of Bladder Cancer: a Meta-Analysis.
Chen L; Cui Z; Liu Y; Bai Y; Lan F
Clin Lab; 2015; 61(8):1101-8. PubMed ID: 26427157
[TBL] [Abstract][Full Text] [Related]
30. Expression based biomarkers and models to classify early and late-stage samples of Papillary Thyroid Carcinoma.
Bhalla S; Kaur H; Kaur R; Sharma S; Raghava GPS
PLoS One; 2020; 15(4):e0231629. PubMed ID: 32324757
[TBL] [Abstract][Full Text] [Related]
31. Combining metabolome and clinical indicators with machine learning provides some promising diagnostic markers to precisely detect smear-positive/negative pulmonary tuberculosis.
Hu X; Wang J; Ju Y; Zhang X; Qimanguli W; Li C; Yue L; Tuohetaerbaike B; Li Y; Wen H; Zhang W; Chen C; Yang Y; Wang J; Chen F
BMC Infect Dis; 2022 Aug; 22(1):707. PubMed ID: 36008772
[TBL] [Abstract][Full Text] [Related]
32. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
33. NMR-based metabolomics study of canine bladder cancer.
Zhang J; Wei S; Liu L; Nagana Gowda GA; Bonney P; Stewart J; Knapp DW; Raftery D
Biochim Biophys Acta; 2012 Nov; 1822(11):1807-14. PubMed ID: 22967815
[TBL] [Abstract][Full Text] [Related]
34. Proteomics Profiling of Bladder Cancer Tissues from Early to Advanced Stages Reveals NNMT and GALK1 as Biomarkers for Early Detection and Prognosis of BCa.
Davalieva K; Kiprijanovska S; Ivanovski O; Trifunovski A; Saidi S; Dimovski A; Popov Z
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834386
[TBL] [Abstract][Full Text] [Related]
35. A prospective pilot evaluation of urinary and immunohistochemical markers as predictors of clinical stage of urothelial carcinoma of the bladder.
Krupski T; Moskaluk C; Boyd JC; Theodorescu D
BJU Int; 2000 Jun; 85(9):1027-32. PubMed ID: 10848689
[TBL] [Abstract][Full Text] [Related]
36. Serum Metabolomics Identifies Dysregulated Pathways and Potential Metabolic Biomarkers for Hyperuricemia and Gout.
Shen X; Wang C; Liang N; Liu Z; Li X; Zhu ZJ; Merriman TR; Dalbeth N; Terkeltaub R; Li C; Yin H
Arthritis Rheumatol; 2021 Sep; 73(9):1738-1748. PubMed ID: 33760368
[TBL] [Abstract][Full Text] [Related]
37. Machine learning models to predict the progression from early to late stages of papillary renal cell carcinoma.
Singh NP; Bapi RS; Vinod PK
Comput Biol Med; 2018 Sep; 100():92-99. PubMed ID: 29990647
[TBL] [Abstract][Full Text] [Related]
38. CXCL5/CXCR2 axis promotes bladder cancer cell migration and invasion by activating PI3K/AKT-induced upregulation of MMP2/MMP9.
Gao Y; Guan Z; Chen J; Xie H; Yang Z; Fan J; Wang X; Li L
Int J Oncol; 2015 Aug; 47(2):690-700. PubMed ID: 26058729
[TBL] [Abstract][Full Text] [Related]
39. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
